# BENEPALI™ (etanercept)
Keywords: BENEPALI, etanercept, rheumatoid arthritis, anti-TNF therapy, bDMARD, EULAR, NICE, DAS28, ACR20, HAQ-DI

> This page provides detailed information about BENEPALI™ (etanercept), a biosimilar therapy for rheumatoid arthritis, including clinical efficacy, safety profile, patient case studies, and guidelines supporting its use.

## Details
- [BENEPALI™ Overview](#): BENEPALI™ demonstrates comparable efficacy and safety to reference etanercept in rheumatoid arthritis patients.
- [Donna - Loss of efficacy on first-line biologic](#donna): A case study discussing treatment options for a patient experiencing secondary failure of adalimumab.
- [Mei - Intolerant to first-line biologic](#mei): A case study exploring cycling to BENEPALI™ after intolerance to adalimumab.
- [Edward - Requires first-line biologic](#edward): A case study highlighting BENEPALI™ as a suitable option for perioperative disease control.
- [Clinical Efficacy](#): BENEPALI™ delivers rapid and sustained control of disease activity with comparable outcomes to reference etanercept.
- [Safety Profile](#): Common adverse reactions include injection site reactions, infections, headache, allergic reactions, and fever.
- [Guidelines](#): UK and European guidelines recommend switching to BENEPALI™ when the first bDMARD fails due to loss of efficacy or adverse events.
- [NICE Recommendations](#): NICE supports anti-TNF therapies for moderate rheumatoid arthritis with DAS28 scores between 3.2 and 5.1.
- [References and Abbreviations](#): Definitions of key terms and references supporting the clinical data presented.